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Abstract
Background:  Hereditary Inclusion Body Myopathy (HIBM) is an autosomal recessive, adult onset, non-inflammatory
neuromuscular disorder with no effective treatment. The causative gene, GNE, codes for UDP-N-acetylglucosamine 2-
epimerase/N-acetylmannosamine kinase, which catalyzes the first two reactions in the synthesis of sialic acid. Reduced sialylation
of muscle glycoproteins, such as α-dystroglycan and neural cell adhesion molecule (NCAM), has been reported in HIBM.
Methods: We treated 4 HIBM patients with intravenous immune globulin (IVIG), in order to provide sialic acid, because IgG
contains 8 μmol of sialic acid/g. IVIG was infused as a loading dose of 1 g/kg on two consecutive days followed by 3 doses of 400
mg/kg at weekly intervals.
Results: For all four patients, mean quadriceps strength improved from 19.0 kg at baseline to 23.2 kg (+22%) directly after IVIG
loading to 25.6 kg (+35%) at the end of the study. Mean shoulder strength improved from 4.1 kg at baseline to 5.9 kg (+44%)
directly after IVIG loading to 6.0 kg (+46%) at the end of the study. The composite improvement for 8 other muscle groups was
5% after the initial loading and 19% by the end of the study. Esophageal motility and lingual strength improved in the patients
with abnormal barium swallows. Objective measures of functional improvement gave variable results, but the patients
experienced improvements in daily activities that they considered clinically significant. Immunohistochemical staining and
immunoblotting of muscle biopsies for α-dystroglycan and NCAM did not provide consistent evidence for increased sialylation
after IVIG treatment. Side effects were limited to transient headaches and vomiting.
Conclusion: The mild benefits in muscle strength experienced by HIBM patients after IVIG treatment may be related to the
provision of sialic acid supplied by IVIG. Other sources of sialic acid are being explored as treatment options for HIBM.
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Background
Hereditary inclusion body myopathy (HIBM; OMIM
600737) is an adult-onset autosomal recessive myopathy
that typically presents with distal muscle weakness, usu-
ally foot drop, in the second or third decade of life [1-3].
The disease progresses to require wheelchair confinement
in two to three decades. The quadriceps muscles are rela-
tively spared, at least clinically, even late in the disease.
Muscle histology shows vacuolated fibers, variation of
fiber size, increased connective tissue, and fibrofatty
replacement of muscle fibers. Inflammation is typically
absent.
HIBM is rare, but a Persian Jewish isolate [4] enabled
investigators to map the condition to chromosome 9p12–
13. The causative gene, GNE, was subsequently identified
and a common mutation, M712T, was found among
affected Persian Jews [5]. The GNE  gene encodes the
bifunctional enzyme, UDP-N-acetylglucosamine (UDP-
GlcNAc) 2-epimerase/N-acetylmannosamine (ManNAc)
kinase, catalyzing the rate-limiting steps in sialic acid syn-
thesis [6,7]. The M712T mutation is located within the
kinase domain of the GNE gene. Nearly 20 other GNE
mutations have been described in HIBM patients of differ-
ent ethnic backgrounds [8-12]; a condition allelic to
HIBM, Distal Myopathy with Rimmed Vacuoles (DMRV),
occurs in Japan [13-15]. HIBM-associated GNE  muta-
tions, whether in the epimerase or the kinase domain,
result in reduced activity of both UDP-GlcNAc 2-epime-
rase and ManNAc kinase [16,17]. These decrements are
considered responsible for reduced production of sialic
acid, a negatively charged sugar that serves as the terminal
carbohydrate on glycoconjugates [18]. Glycosylation of
proteins is critical for proper folding of nascent proteins,
resistance to proteases, intracellular trafficking, and cell-
cell interactions [19,20].
The pathogenic mechanism of muscle fiber degeneration
in HIBM remains unknown. However, evidence suggests
that decreased availability of sialic acid causes hyposia-
lylation of muscle glycoproteins, whether involving gly-
cans in general [17,21], O-linked glycans [22], polysialic
acid on neural cell adhesion molecules (PSA-NCAM)
[23], or specific O-mannosylated glycosyl residues on α-
dystroglycan [24]. These latter oligosaccharides govern
interactions of α-dystroglycan with extracellular matrix
proteins [25,26], and their deficiency is responsible for
several congenital muscular dystrophies, including
Walker-Warburg syndrome, Muscle-Eye-Brain disease,
and Fukuyama's muscular dystrophy [27-29]. In HIBM,
decreased sialylation of α-dystroglycan could impair
interaction with other skeletal muscle proteins essential
for function.
We reasoned that provision of sialic acid to HIBM patients
could help normalize the sialylation status of muscle glyc-
oproteins and provide clinical benefit. Because no
approved source of free sialic acid is available, we deliv-
ered this charged sugar via intravenous immune globulin
G (IVIG), a glycoprotein that contains 8 μmoles of sialic
acid per gram [30]. Maintaining high levels of serum IgG
could result in continuous breakdown of the glycoprotein
by neuraminidase, providing sufficient quantities of free
sialic acid to the blood, scavenger cells and eventually
muscle tissue. Side effects included headaches, nausea and
vomiting, particularly after the second day of the loading
dose; these resolved within 48 hours. Improvements in
quantitative muscle testing and the six-minute walk were
recorded. Qualitative improvements in activities of daily
living, muscle strength, and endurance were noted in all
four treated patients.
Methods
Protocol design
Four patients with molecularly proven HIBM were
enrolled in a protocol approved by the NHGRI Institu-
tional Review Board, and gave written, informed consent.
Baseline evaluations at the NIH Clinical Center consisted
of a complete history and physical examination, labora-
tory studies including quantitative immune globulins, a
cardiac evaluation with a chest radiograph, electrocardio-
gram and echocardiogram, an ophthalmologic examina-
tion, and a neuromuscular evaluation that included an
MRI of the calf and/or thigh. A baseline Rehabilitation
Medicine evaluation included quantitative muscle
strength testing, i.e., isometric fixed dynamometry [31] of
10 muscle groups, and measurements of tongue strength
[32,33]. Strength was tested with subjects positioned
supine and sitting on a treatment table, with stabilization
provided by belts or examiners. Subjects performed two
maximal voluntary isometric contractions of 10 muscle
groups bilaterally separated by at least 30 s of rest. Joint
angles were kept constant throughout the study via goni-
ometric measurements. Cuffs were placed around the
desired limb and were attached to a force transducer fixed
to a stationary bed frame. The means of two trials were
used for data analyses. Functional testing included a mod-
ified barium swallow evaluation, functional reach tests
[34], timed up and go [34], and a 6-minute walk test to
measure endurance [35]. A quadriceps muscle biopsy was
taken for histology, immunohistochemistry and immu-
noblotting. Pulmonary function testing was performed in
patients 3 and 4.
After baseline testing, patients received a loading dose (1
g/kg) of immune globulin (Octagam 5% or Gamunex
10%) by continuous intravenous infusion on two consec-
utive days. Patients were hydrated before and after the
infusions with 500 mL of either normal saline or half-nor-BMC Neurology 2007, 7:3 http://www.biomedcentral.com/1471-2377/7/3
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mal saline. They were also premedicated with 50 mg of IV
diphenhydramine and either 650 mg of acetaminophen
or 250 mg of naproxen. One week after the two loading
doses, the patients began receiving weekly maintenance
doses of IVIG at 400 mg/kg for a total of 3 maintenance
infusions. Hydration and premedication were also pro-
vided for these infusions. Evaluations of quantitative
muscle testing, grip and pinch strength, 6-minute walk
test and functional reach studies were performed directly
after the loading dose and at the end of the study. Tongue
strength measurements, a modified barium swallow, an
ophthalmologic evaluation and a muscle biopsy were
repeated at the end of the study. Laboratory testing was
performed after each infusion and at the end of the study
to monitor for safety and to follow levels of immune glob-
ulins.
Muscle biopsies
Open quadriceps muscle biopsies were performed before
and 3–4 days after the last dose of IVIG. Specimens were
processed for muscle enzyme histochemistry, immunocy-
tochemistry, and immunoblotting as described below.
Alpha-dystroglycan and NCAM immunocytochemistry
Coded serial cryosections (5 μm each), obtained before
and after IVIG treatment from the patients, one normal
control (N1), and one individual with sporadic IBM (N2),
were fixed in acetone for 5 min and pre-incubated with
phosphate-buffered saline (PBS) containing 2% bovine
serum albumin (BSA). The sections were then incubated
overnight at 4°C with antibodies against α-dystroglycan
(VIA4-1 and IIH6, Upstate, Lake Placid, NY, USA) diluted
at 1:100, or anti-NCAM (123C3, Santa Cruz Biotechnolo-
gies, CA, USA) diluted at 1:200. Immunoreactivity was
detected using FITC-labeled goat anti-mouse IgG or IgM
(Molecular Probes, Eugene, OR) at a dilution of 1:500 for
1 h. Negative controls included the omission of each pri-
mary antibody in every staining. The sections were
mounted in 30% glycerol-based medium and viewed
using fluorescent microscopy.
Immunoblotting
Muscle tissues were homogenized in 200 μL of CelLytic
(CelLytic, Sigma, St Louis, MO, USA), consisting of a mild
detergent, bicine buffer and 150 mM NaCl, with protease
inhibitors (Complete Mini®, Roche, Mannheim, Ger-
many). The lysates were sonicated and microfuged at
8000 g for 10 min at 4°C. The protein concentration of
the supernatant was determined using the BCA protein
assay (Pierce, Rockford, IL, USA) and equal amounts of
protein (25–50 μg) were loaded and electrophoresed on
4–12% Tris-Glycine gels (Novex, Invitrogen, Carlsbad,
CA, USA). Resolved proteins were electrophoretically
transferred to a 0.45 μm Hybond ECL nitrocellulose
membrane (Amersham Pharmacia Biotech, IL, USA). Sub-
sequently, membranes were blocked with 10% fat-free
milk in PBS with 0.1% Tween 20 (PBST) for 30 min and
then incubated with antibodies against NCAM (123C3,
Santa Cruz Biotechnologies, CA, USA), α-dystroglycan
(clone IIH6C4, 05–593, Upstate, Lake Placid, NY, USA) or
β-actin (AAN01, Cytoskeleton, Denver, CO, USA) fol-
lowed by horseradish peroxidase-conjugated secondary
antibodies in PBST containing 3% fat-free milk. Immuno-
reactive bands were visualized by enhanced chemilumi-
nescence using the Amersham ECL Western Blotting
Detection Reagent (GE Healthcare, Buckinghamshire,
UK). Density analysis was performed on digital images
obtained with the Kodak Image station and software (Per-
kin Elmer, Boston, MA, USA). The protein levels were nor-
malized to those of β-actin to correct for differences in
protein loading and/or transfer.
For enzyme treatment experiments, protein samples (25
μg) were incubated with neuraminidase (N-6514, Sigma,
St Louis, MO, USA), 1 mU/μg of protein, for 30 min at
37°C. Undigested and digested samples were analyzed by
immunoblotting.
Isoelectric focusing
For isoelectric focusing (IEF) of transferrin, whole serum
was iron-saturated and isofocused on pH4-6.5 PhastGels
(Amersham Biosciences, Piscataway, NJ, USA) as
described [36,37]. Transferrin isoforms were visualized by
incubation with rabbit anti-human transferrin antibody
(Dakocytomation, Denmark) followed by silver staining
(Amersham Biosciences, Piscataway, NJ, USA). For IEF of
apolipoprotein C-III (Apo C-III), whole serum proteins
were acetone-delipidated and resuspended in 8 M urea.
Subsequently, Apo C-III was isolated and concentrated by
centrifugation through centricon filters (Millipore, Bed-
ford, MA, USA) and isofocused on PhastGels pH4-6.5
(Amersham Biosciences, Piscataway, NJ, USA). The pro-
teins were transferred by diffusion blotting onto nitrocel-
lulose membranes and visualized by incubation with goat
anti-Apo CIII antibodies (Chemicon, Temecula, CA, USA)
and Enhanced ChemiLuminescence detection (Amer-
sham Biosciences, Piscataway, NJ, USA) as described
[37,38].
Results
Patients
Patient 1 is a 29-year-old Iranian-Jewish woman diag-
nosed at age 24 years. She presented at age 17 with inabil-
ity to abduct her legs against any resistance on an exercise
machine; other muscle groups were strong. Following her
first pregnancy at age 20, she noticed weakness, difficulty
climbing stairs, and tripping and falling that progressed in
frequency over the next 3 years from once a month to
once a week. A muscle biopsy and genetic testing con-
firmed the diagnosis of HIBM with homozygous M712TBMC Neurology 2007, 7:3 http://www.biomedcentral.com/1471-2377/7/3
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mutations in GNE. At age 25, she noted difficulty fasten-
ing snaps and could not raise her arms to pull back her
hair. Progression was gradual, with more significant
decline following illnesses. Treatments included solume-
derol, 1 g intravenously for 3 days, which resulted in
improved strength but was followed by relapse. On one
occasion, IVIG (dose unknown) was given over 3 days,
providing no improvement but complicated by aseptic
meningitis requiring hospitalization. For the 6 months
prior to admission, the patient used a wheelchair and
required assistance walking and with transfers. Medica-
tions included sertraline for depression and anxiety, and
vitamins.
At the NIH Clinical Center, the patient was wheelchair
dependent, but could go from sit to stand and ambulate a
few feet with support. She had bilateral foot drop and sig-
nificant weakness of upper and lower extremities, with
some sparing of the quadriceps. Muscle atrophy was uni-
versally apparent. Cranial nerves and sensation were
intact. MRI of the calf showed pronounced fatty involu-
tion of the musculature bilaterally, worse proximally. The
lateral soleus and posterior tibial muscles were somewhat
spared distally. A quadriceps muscle biopsy revealed
moderate type II fiber predominance. The muscles were
atrophic (type II worse than type I) and demonstrated
necrosis, active degeneration, and red rimmed vacuoles,
consistent with severe chronic myopathy without inflam-
mation. Imunohistochemical staining for NCAM, a sur-
face glycoprotein reflecting muscle regeneration [23,39],
showed a significant number of positive fibers.
Patient 2 is the 42-year-old brother of patient 1. He was
diagnosed with HIBM at 37 years of age, following the
diagnosis of his sister. Weakness upon raising his arms
overhead first appeared at age 27. At 34, he began tripping
and, in the subsequent year, had difficulty climbing stairs
and lifting his son. The upper extremities were most
affected, but leg weakness was evident by decreased
endurance, speed of walking, and getting in and out of a
car. He occasionally used his hands to lift his legs. Symp-
toms were largely stable, but exacerbated by emotional
events. He did not receive any treatment for his myopathy,
and medications included only multivitamins.
At the NIH Clinical Center, there was wasting of the tri-
ceps and the interosseus and thenar muscles of the hand.
Contractures of approximately 5–10 degrees were present
in the elbows, with decreased range of motion upon supi-
nation of the forearm. The patient had no foot drop. Mus-
cles of the shoulder girdle, pinch, grip, and proximal
lower extremities exhibited weakness. The gait was nor-
mal, and cranial nerves and sensation were intact. MRI of
the thigh revealed advanced atrophy with fatty involution
in the proximal posterior compartment and adductor
magnus muscles bilaterally. The sartorius and rectus fem-
oris muscles were also involved. There was relative sparing
of the quadriceps with the exception of the rectus femoris
muscles. On biopsy, the quadriceps muscle showed sev-
eral small vacuolated fibers with a few degenerating fibers,
but no inflammation. Immunohistochemical staining
was negative for NCAM, indicating negligible damage to
individual muscle fibers.
Patient 3 is a 39-year-old woman of Bohemian/Czech/
French Canadian ancestry diagnosed with HIBM at the age
of 31 years. Following a year of progressive tripping and
falling, she awoke one day with numbness from the waist
down that spread to her entire body. She was diagnosed
with mild multiple sclerosis, based on the presence of oli-
goclonal bands in her cerebrospinal fluid and a brain MRI
showing a possible "spot." Muscle biopsy also provided
evidence of inclusion body myopathy. Currently, she has
difficulty arising from a supine position due to weak
abdominal muscles, weakness in her hands, arms, and
shoulders, and inability to climb stairs. She wears ankle
braces to walk. She uses bronchodilators for asthma and
sertraline for depression. Confirmatory mutational analy-
sis demonstrated compound heterozygous GNE  muta-
tions, i.e., R246Q and A631V, affecting the epimerase and
kinase domains, respectively.
At the NIH Clinical Center, the patient had bilateral foot
drop with a compensated gait. She was able to transfer
independently from sit to stand and from stand to sit.
There was proximal muscle and neck weakness and lim-
ited endurance. Cranial nerves and sensation were intact.
MRI of the calf showed end-stage myopathy with
advanced fatty involution, but with preservation of mus-
cle volume. Signal alteration was present in areas of non-
atrophic muscle. The popliteal muscles in the upper calves
and the distal posterior tibial muscles were relatively
spared. On biopsy, the quadriceps muscle showed signifi-
cant necrosis with replacement of muscle by fat and con-
nective tissue, but without inflammation. NCAM staining
was minimal.
Patient 4 is the 46-year-old brother of patient 3. He was
diagnosed with HIBM at the age of 33 years following a
one-year history of progressive tripping and falling,
decreased muscle strength and inability to lift his foot. As
a cabinetmaker, he relied on this action to support the
cabinets as he made them. A muscle biopsy was initially
read as consistent with either polymyositis or inclusion
body myopathy, but intravenous steroids provided no
relief, and HIBM was diagnosed. Plateaus were inter-
spersed with declines, which occurred with lack of exercise
but not with illnesses. The lower extremity weakness
extended throughout the body. The patient currently
wears ankle braces to walk, uses an electric wheelchair forBMC Neurology 2007, 7:3 http://www.biomedcentral.com/1471-2377/7/3
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distances, and has assistive devices to drive. He has diffi-
culty holding a pen. Medications include acyclovir, Meta-
mucil, multivitamins, tramadol and diazepam.
At the NIH Clinical Center, there was muscle wasting of
the triceps and the interosseus muscles of the hands,
along with tightness of the heel cords, hips, and ham-
strings. The patient was partially independent when going
from sit to stand, and when executing transfers to and
from his wheelchair. He could ambulate a few steps using
ankle-foot orthotics and support from the wall. He had
significant weakness in the proximal upper extremities,
triceps, wrist and hand, and decreased strength on hip
flexion, hip extension, ankle dorsiflexion, and plantar
flexion. Deep tendon reflexes could not be elicited in the
upper or lower extremities. Sensation and cranial nerve
functions were intact. MRI of the calf showed end-stage
myopathy with advanced fatty involution but preserva-
tion of muscle contours. Signal alteration occurred in
areas of the remaining muscle. There was relative sparing
of the popliteus, the tibialis posterior, and the flexor digi-
torum longus muscles. Quadriceps muscle histology
revealed vacuolated and moth-eaten muscle fibers, with
degeneration and regeneration. Connective tissue was
slightly increased with no signs of inflammation. Immu-
nohistochemical staining with NCAM was negative.
Effects of IVIG on serum IgG
IgG levels during the course of the study are shown in Fig-
ure 1. The loading doses of IVIG brought the serum IgG
levels to approximately 4 times the baseline, but this con-
centration of IgG was not sustained by the weekly infu-
sions of 400 mg/kg of IVIG. Throughout the course of the
infusion, the patients' serum IgG concentrations ranged
from 2 to 4 times the average normal level.
Muscle strength
On quantitative muscle testing, both distal and proximal
muscle groups showed improvement after IVIG treat-
ment. The greatest absolute improvement was in quadri-
ceps strength, as reflected in the capacity to perform work
in knee extension. Considering both sides of all 4 patients,
mean quadriceps strength improved from 19.0 kg at base-
line, to 23.2 kg (+22%) directly after IVIG loading, to 25.6
kg (+35%) at the end of the study. Considered individu-
ally, the 4 patients exhibited a 13–150% improvement in
the dominant right leg after IVIG treatment (Figure 2). The
change in left leg quadriceps strength varied from -3% to
+48%. Shoulder abduction also showed significant
improvement. Considering both sides of all 4 patients,
mean shoulder strength improved from 4.1 kg at baseline,
to 5.9 kg (+44%) directly after IVIG loading, to 6.0 kg
(+46%) at the end of the study. Considering each patient
individually, shoulder abduction on the right side
improved 24–79% in three patients and fell 14% in
patient 3 (Figure 2). On the left side, shoulder abduction
improved 13–184%.
Eight other muscle pairs (right and left), associated with
hip flexion, ankle dorsiflexion, elbow flexion and exten-
sion, wrist flexion and extension, grip, and pinch, were
also evaluated. These muscle groups exhibited variable
differences in strength before and after IVIG treatment
(Table 2), but the preponderance showed improvement.
In fact, on average, the composite improvement for these
8 muscle groups was 5% after the initial IVIG loading and
19% by the end of the study. Tongue strength, which is
not known to be affected in HIBM, improved ~5%, from
a mean of 63.1 kp at baseline to a mean of 66.2 kp at the
end of the study.
Functional testing
Functional studies included functional reach, timed up
and go, and the 6-min walk test. Patient 1 could not per-
form any of these tests. Patient 4 could not perform the 6-
min walk test.
In patient 2, the functional reach after IVIG treatment
increased from 7.3 in to 10.2 in (40%) on the right and
from 6.0 in to 8.8 in (47%) on the left. However, the func-
tional reach declined in patients 3 and 4 by 8% and 19%,
respectively. The time it took to rise from a chair (timed
up and go) improved 1.94 s (27%) for patient 2 and 0.81
s (8%) for patient 3; it worsened by 0.84 s (5%) in patient
4. Endurance, as measured by the 6-min walk test,
improved after IVIG treatment from 1633 ft to 1744 ft
(7%) in patient 2 (normal mean for age and size, 1997 ft)
and from 983 ft to 1065 ft (8%) in patient 3 (normal
mean, 1637 ft).
Improvements in the two patients with abnormal modi-
fied barium swallows were also noted. Patient 1 had nor-
mal esophageal peristalsis with only mild delays after
IVIG and patient 3 had no reflux or pooling with only
delayed initiation after the treatment.
Patients displayed qualitative or subjective improvements
as well. Patient 1 claimed improved strength, energy, and
balance and needed less support to walk. She could get in
and out of a bed or chair more easily. Brushing her hair
was easier. She was able to open a bottle of water and cut
a bagel without help. After IVIG treatment, she could snap
her fingers and produce noise, which she had been unable
to do for years. Patient 2 noted improvements in getting
out of bed or a car. He could easily wash his hands and
face, which was a struggle before treatment. He could
reach further and could lift his children; he had more
energy to play with them. Both he and his wife noticed
that he walked faster. Patient 3 noted improvements with
getting out of bed and up from a sitting position. SheBMC Neurology 2007, 7:3 http://www.biomedcentral.com/1471-2377/7/3
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needed less support to accomplish her activities of daily
living and appreciated increased energy. Patient 4 stated
that he felt better, but was unable to provide specific
examples. The subjective improvements lasted approxi-
mately three weeks, after which each of the patients noted
a decline in function.
Serum glycoproteins
Serum transferrin contains four terminal sialic acid resi-
dues on its N-linked oligosaccharides [36,37]. On isoelec-
tric focusing, all four oligosaccharides were sialylated in
all four patients before IVIG treatment, just after loading,
and at the end of the treatment period [see Additional file
1]. Similarly, the O-linked serum glycoprotein Apo C-III
[37,38] exhibited a normal contingent of sialylation in all
four patients before and after IVIG treatment [see Addi-
tional file 1].
Muscle studies
Muscle MRI examinations were not repeated after IVIG
treatment, because one month was not deemed a suffi-
cient amount of time to achieve visible improvement.
Standard histology of muscle biopsies showed no differ-
ence before compared with after IVIG treatment. The post-
treatment biopsy of patient #3 was unsuitable for inter-
pretation, but muscle biopsies from patients 1, 2, and 4
before and after IVIG treatment were available for staining
with anti-α-dystroglycan antibodies (VIA4I and IIH6). No
consistent differences were seen before and after treat-
ment (Figure 3A–F). Immunoblotting showed no consist-
ent increase in the glycosylation status of α-dystroglycan
Serum IgG levels in patients during the course of treatment with IVIG Figure 1
Serum IgG levels in patients during the course of treatment with IVIG. Arrows indicate loading doses (1 g/kg) and 
maintenance doses (0.4 g/kg).
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(using the IIH6 antibody) after IVIG treatment (Figure
3G).
NCAM is a sialylated glycoprotein that plays a significant
role in muscle fiber development, innervation and regen-
eration, and whose abundance on the surface of muscle
cells reflects the extent of muscle denervation or damage
[23,39-42]. Patient 1 exhibited the greatest amount of
muscle NCAM before IVIG (Figure 4A), i.e., 4-fold that of
the N1 (normal) control, relative to actin, as determined
by densitometry. After IVIG treatment, the muscle NCAM
of patient 1 decreased by 34%. The amount of NCAM
decreased by 28% in patient 2, but increased by 58% in
patient 4, relative to actin after IVIG administration. In all
cases, the HIBM patients' NCAM bands ran lower than the
control, reflecting a decreased sialic acid content of this
glycoprotein. This was verified for patient 2 by using sial-
idase to remove terminal sialic acid residues (Figure 4B).
Sialidase treatment resulted in greater mobility of the nor-
mal muscle NCAM protein, but not that of patient 2 (Fig-
Quadriceps and shoulder abduction testing in four patients with HIBM Figure 2
Quadriceps and shoulder abduction testing in four patients with HIBM. On average, quadriceps strength increased 
22% after IVIG loading and 35% at the end of the study. Shoulder abduction strength increased 44% after IVIG loading and 46% 
at the end of the study.
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ure 4B). Sialidase treatment did, however, reduce the
apparent size of muscle NCAM in patient 1, indicating the
presence of some sialylation.
NCAM immunohistochemical staining of HIBM muscle
(patient 1, 2, and 4) after IVIG treatment did not reveal
any consistent differences compared with pre-treatment
staining (data not shown).
Side effects
All patients experienced fatigue and headache following
the second loading dose of 1 g/kg IVIG. Patients 1, 2, and
3 had several episodes of nausea and vomiting; patient 2
said it resembled having influenza. Patient 4 had head-
ache and neck stiffness. Patients 1 and 2 experienced ano-
rexia, and patient 2 had abdominal distension and
constipation. The headaches were treated with naproxen
or acetaminophen. Patient 3 required zofran for relief of
the nausea and vomiting. All symptoms resolved by 72 h
and did not recur with subsequent maintenance infusions
of IVIG. A urinary tract infection was diagnosed inciden-
tally in patient 1, and was treated. The follow-up ophthal-
mologic evaluation in patient 4 revealed a cottonwool
spot near the left optic disc.
Patients 3 and 4 responded to the IVIG with increased sed-
imentation rates, as high as 96 mm/h (Table 1). Liver
enzymes rose slightly in patients 1, 2 and 4; the highest
levels were obtained in patient 2, with an ALT of 81 U/L
and an AST of 68 U/L. These values subsequently returned
to normal. Serum cholesterol levels generally fell, from a
mean of 200 mg/dL at baseline to 147 mg/dL just after
loading and 173 mg/dL at the end of the study. Remarka-
bly, the four patients excreted 6.4 to 30.8 g/d of glucose in
their urine just after the IVIG load, compared with ≤0.1 g/
day before and after the study. There were no significant
changes in serum electrolytes, glucose, calcium, phospho-
rus, or bilirubin.
Table 2: Strength of muscle groups of 4 HIBM patients at baseline and after IVIG treatment.
Hip Flexion Ankle Dorsiflexion Elbow Wrist Hand
Flexion Extension Flexion Extension Grip Pinch
Baselinea,b 3.21 ± 0.84 3.50 ± 2.15 4.71 ± 1.42 3.36 ± 1.09 5.24 ± 0.86 4.55 ± 0.46 7.43 ± 1.63 1.02 ± 0.22
Post-Loadb 3.93 ± 0.74
(+22%)
2.53 ± 1.55
(-28%)
5.56 ± 1.60
(+18%)
3.30 + 0.98
(-2%)
5.81 ± 1.07
(+11%)
5.15 ± 0.58
(+13%)
7.85 ± 1.65
(+6%)
1.03 ± 0.16
(+1%)
End of studyb 3.63 ± 0.62
(+13%)
4.28 ± 2.87
(+22%)
5.45 ± 1.55
(+16%)
3.36 ± 1.03
(0%)
6.25 ± 1.15
(+19%)
5.78 ± 0.93
(+27%)
7.83 ± 1.59
(+5%)
1.37 ± 0.25
(+35%)
aValues are given in kg as means ± SEM. Percent changes are in parentheses. Values for both the right and left sides were included in the analyses.
bBaseline: Before treatment; Post-Load: Day 1 after IVIG load (1 g/kg × 2); End of study: 4 weeks after the initial IVIG load.
Table 1: Laboratory values at baseline, after loading with IVIG (1 g/kg × 2), and at the end of IVIG treatment.
Baseline Post-load End of study Normal range
P a t i e n t 1 2 3 4 12341234
Hemoglobin (g/dL) 13.1 14.4 13.2 14.3 11.2 13.8 11.2 13 12.1 13.8 12.3 11.4 11.1–16.7
WBC (K/uL) 8.94 7.57 7.39 7.28 6.82 6.11 8.06 2.99 6.94 6.16 6.34 4.85 3.3–9.6
Platelets (K/uL) 282 230 284 225 226 209 262 207 267 222 256 220 154–380
ESR (mm/h) 17 7 23 14 39 38 96 86 30 20 57 73 0–42
Creatinine (mg/dL) 0.3 0.7 0.5 0.4 0.4 0.8 0.6 0.6 0.3 0.7 0.6 0.5 0.7–1.4
BUN (mg/dL) 15 14 12 13 12 7 8 8 16 15 13 17 8–22
ALT (U/L) 42 36 18 36 31 37 16 30 60 81 18 62 6–41
AST (U/L) 30 31 22 23 21 31 15 23 36 68 31 52 9–34
CPK (U/L) 320 475 98 130 244 451 50 87 229 629 78 94 38–386
Cholesterol (mg/dL) 195 203 195 207 133 153 144 156 168 179 175 170 100–200
Total protein (g/dL) 6.4 6.1 6.1 6.3 7.8 8.7 9.5 9.1 7.1 7.2 7.3 7 6.0–7.6
Albumin (g/dL) 3.7 3.7 3.2 3.5 2.9 3.4 2.6 3 3.3 3.5 2.8 3.1 3.7–4.7
IgG (mg/dL) 1280 1180 955 997 3550 4280 5670 4440 2150 2350 2340 2310 642–1730
Urine protein (mg/d) 150 92 294 97 <30 <30 <30 <30 79 95 364 142 30–150
Urine glucose (g/d) 0.07 0.07 0.07 0.09 14.4 30.8 6.4 12.2 0.07 0.07 0.10 0.08 0–0.49
Abnormal values are in bold. Normal range encompasses values for males and females.
Baseline values are average of results on two different days.BMC Neurology 2007, 7:3 http://www.biomedcentral.com/1471-2377/7/3
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Discussion
Homozygous or compound heterozygous mutations in
either the epimerase or kinase domain of GNE  cause
decreased UDP-GlcNAc 2-epimerase and ManNAc kinase
activities in the cells of HIBM patients [16,17]. However,
the pathogenic mechanisms responsible for the myopathy
of HIBM have not been determined. Measurements of the
sialic acid content of glycoproteins have given variable
results [17,21-24,43-45]. Using sialylated α-dystroglycan-
specific antibodies, Huizing et al. first reported decreased
muscle α-dystroglycan sialylation in four HIBM patients,
each having one mutation in the epimerase domain and
one in the kinase domain of GNE [24]. Noguchi et al. fol-
lowed with findings of fiber-to-fiber variability in the
hyposialylation of α-dystroglycan in the muscles of
patients with DMRV, allelic with HIBM [17]. Saito et al.
reported hyposialylation of muscle glycoproteins in a sin-
gle patient with DMRV [21], but Hinderlich et al. and
Salama et al. showed no decrease in sialylation of proteins
in myoblasts cultured from HIBM patients homozygous
for the Persian Jewish GNE mutation, i.e., M712T [43,44].
Broccolini et al. recently reported hyposialylated muscle
α-dystroglycan in 4 of 5 HIBM patients, with no effect on
binding to laminin [45]; they surmised that the sialylation
status of α-dystroglycan is not critical to the protein's
function. Ricci et al. used NCAM as an indicator of the
extent of muscle glycoprotein sialylation; in HIBM, mus-
cle NCAM was found to be hyposialylated [23]. The diver-
gence of these findings allows for the possibility that
sialylation abnormalities represent epiphenomena in
HIBM, and GNE mutations could cause disease by affect-
ing cellular functions not influenced by sialylation.
Expression of α-dystroglycan in quadriceps muscle from HIBM patients Figure 3
Expression of α-dystroglycan in quadriceps muscle from HIBM patients. A-F. Immunohistochemistry using antibod-
ies to IIH6. No consistent difference in staining was apparent before (A,C,E) compared with after (B,D,F) IVIG treatment. The 
specimen shown in A was sampled from a deteriorating area. G. Immunoblots of muscle from a normal individual (N) and 
HIBM patients 1, 2, and 4, labeled with antibodies to α-dystroglycan. No consistent difference in IIH6 staining (reflecting the 
sialylation status of α-dystroglycan) was apparent before (Pre) compared with after (Post) IVIG treatment. β-Actin bands pro-
vide an indication of the level of protein loading.
A
F
E
D
C
B
Pre IVIG
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N
148kDa
Pre   Post Pre      Post Pre  Post
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β-actin
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Indeed, while we verified the hyposialylation of muscle
NCAM in our HIBM patients (Figure 4A,B), we found that
decreased sialylation of glycoproteins is not a constant
finding in HIBM. Isoelectric focusing studies revealed nor-
mal N-linked glycosylation of serum transferrin and O-
linked glycosylation of Apo C-III [see Addional file 1]. In
addition, sialylated α-dystroglycan was not decreased in
the muscle of our four HIBM patients prior to IVIG
administration. This could be because patients vary with
respect to their specific GNE mutations, the extent of their
sialic acid deficiency, and the degree to which their muscle
proteins are sialylated, even when sampling the same
Expression of sialylated NCAM in muscle of HIBM patients Figure 4
Expression of sialylated NCAM in muscle of HIBM patients. A. Muscle from two control individuals exhibit NCAM 
mobility consistent with a higher molecular weight, indicative of sialylation. N1 is normal and N2 has sporadic IBM; note 
increased NCAM in this person's muscle. The muscle of patient 1 also has an increased amount of NCAM; patients 2 and 4 
have moderate amounts of NCAM. The NCAM of the HIBM patients migrates with greater mobility than normal, indicating 
lack of sialylation. The amount of muscle NCAM decreased after (Post) compared with before (Pre) IVIG treatment in patients 
1 and 2, but increased in patient 4. B. Sialidase treatment increased the mobility of control muscle (N1 and N2). The mobility of 
muscle NCAM was not altered by sialidase treatment in patient 2, but it was increased by sialidase treatment in patient 1.
Sialidase (-)     (+)       (-)      (+) (-)     (+)     (-)     (+)       (-)     (+)      (-)     +)
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Pre      Post Pre           Post
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muscle. Conditions of the immunohistochemical staining
could differ, as could the specificity and sensitivity of the
antibodies.
With normal baseline glycosylation of serum glycopro-
teins and muscle α-dystroglycan in HIBM, we had no
opportunity to demonstrate improvement in these
parameters after IVIG treatment. Muscle NCAM was hypo-
sialylated before IVIG administration, but we could not
discern consistent improvements in NCAM sialylation,
either by immunohistochemistry or by immunoblotting,
after IVIG treatment. One possible explanation is that the
amount of sialic acid provided by IVIG was inadequate to
increase glycoprotein sialylation. We estimate that normal
adult urinary free sialic acid, a reasonable measure of daily
production, approximates 0.3 mmol [46]. Our IVIG load-
ing doses (2 g/kg) should provide 8 μmol/g or ~1 mmol
of sialic acid, roughly 3 days' worth of normal sialic acid
production. This may or may not be sufficient to achieve
a detectable or functional increase in the glycosylation of
muscle protein.
We would expect a decrease in muscle NCAM to accom-
pany the decrease in muscle degeneration hoped for with
IVIG treatment, and this occurred in patients 1 and 2. The
increased amount of hyposialylated NCAM in patient 4
after IVIG treatment contradicts this finding and reflects
variability either in response to treatment or in muscle
sampling.
In contrast to the absence of consistent effects on histolog-
ical and immunological markers of sialylation, IVIG treat-
ment improved objective and subjective measures of
muscle strength and function in HIBM patients. Muscles
that had greater strength at baseline, such as the quadri-
ceps, appeared to benefit more than muscles that were
already extensively damaged; results were variable but, on
average, the improvement in strength exceeded 20% in
the quadriceps and shoulders. Even though the acquisi-
tion of functional abilities was short-lived, all the patients
were pleased, and two of them wished to pursue IVIG
treatments independently. It is not surprising that acute
clinical improvements were not accompanied by histolog-
ical changes, since morphological changes should require
long-term treatments and, perhaps, muscle regeneration.
There are several possible explanations for the beneficial
clinical effects of IVIG despite the absence of evidence for
increased glycoprotein sialylation. The salutary responses
to IVIG could have been due to its anti-inflammatory
actions [47,48]; patient 3 had previous evidence of central
nervous system inflammation and patient 4 had a muscle
biopsy read as possible polymyositis. Nevertheless, the
myopathy in HIBM is not considered to be inflammatory,
and muscle biopsies performed at the NIH on all four
patients lacked signs of inflammation. A second possibil-
ity is that minor increases in sialylated muscle glycopro-
teins, responsible for improved muscle function, were
present transiently after IVIG treatment, but were undetec-
table in our assay. A third possibility is that the muscle we
biopsied, the quadriceps, had minimal baseline reduction
in glycoprotein sialylation so that any increased sialyla-
tion after therapy could not be appreciated. Finally, the
beneficial clinical effects might not be at all related to sia-
lylation.
Ours was clearly a pilot study, clarifying some issues for
future therapeutic investigations. For example, we docu-
mented that muscle strength testing provides an objective
outcome parameter, with fixed dynamometry detecting
small and large changes in strength, complemented by
more subjective measures of muscle function [49]. We
also determined that muscle histology, immunohistology
and sialylated glycoprotein quantitation by immunoblot-
ting do not provide reliable measures of improvement, at
least in the short term. These parameters require further
investigation using longer treatment regimens and greater
amounts of sialic acid supplementation. One possibility
would be to administer only the Fc portion of immune
globulin, which contains the bulk of the sialic acid resi-
dues and has ten times the anti-inflammatory efficacy of
the complete molecule [47]. Even so, IVIG is not likely to
be the treatment of choice for HIBM, because it must be
administered repeatedly, its mode of delivery requires
hospitalization, its cost is considerable, and it has side
effects. However, the finding of definitive improvements,
albeit moderate and transient, attributable to IVIG sug-
gests that the provision of sialic acid holds therapeutic
promise.
Our next pursuit will involve administration of ManNAc,
an uncharged sugar situated in the sialic acid synthetic
pathway after the rate-limiting UDP-GlcNAc 2-epimerase
step. Residual ManNAc kinase activity in HIBM patients,
or ancillary kinases such as GlcNAc kinase [50], might
convert ManNAc into ManNAc-6P for subsequent synthe-
sis of sialic acid. In fact, hyposialylated, GNE-deficient
mouse embryonic stem cells became resialylated after
their growth medium was supplemented with ManNAc
[51]. Furthermore, ManNAc supplementation has
resulted in prolonged survival of a mouse model of HIBM
[52], and could yield increased glycoprotein sialylation in
the tissues of humans with HIBM.
Conclusion
Our findings indicate that IVIG treatment has a salutary
clinical effect on the myopathy of HIBM. Since HIBM
results from defective sialic acid biosynthesis and is not
associated with inflammation, the benefits of IVIG treat-
ment could be related to the high sialic acid content ofBMC Neurology 2007, 7:3 http://www.biomedcentral.com/1471-2377/7/3
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IgG. These results prompt consideration of other sources
of sialic acid as therapy for HIBM, and identify suitable
outcome parameters for future clinical trials.
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